Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were treated with trastuzumab plus docetaxel. Patholo...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnould, L, Gelly, M, Penault-Llorca, F, Benoit, L, Bonnetain, F, Migeon, C, Cabaret, V, Fermeaux, V, Bertheau, P, Garnier, J, Jeannin, J-F, Coudert, B
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361112/
https://www.ncbi.nlm.nih.gov/pubmed/16404427
http://dx.doi.org/10.1038/sj.bjc.6602930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361112/
https://www.ncbi.nlm.nih.gov/pubmed/16404427
http://dx.doi.org/10.1038/sj.bjc.6602930

Ejemplares similares